GILD · Gilead Sciences, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cell Therapy product sales | $407M | first quarter 2026 | -12.3% |
|
|
|||
| Liver Disease portfolio sales | $767M | first quarter 2026 | +1.2% |
|
|
|||
| Non-GAAP product gross margin non-GAAP | 87.5% | first quarter 2026 | — |
| Product gross margin | 79.2% | first quarter 2026 | — |
| Product sales excluding Veklury | $6.8B | first quarter 2026 | — |
| Trodelvy sales | $402M | first quarter 2026 | +37.2% |
|
|
|||
| Veklury sales | $144M | first quarter 2026 | -52.3% |
|
|
|||
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GILD
this stock
Gilead Sciences, Inc.
|
$160.55B | +7.2% | +10.0% | 17.6 | 2.0% |
|
LLY
ELI LILLY & Co
|
$1.13T | +10.5% | +44.7% | 42.5 | 1.1% |
|
JNJ
Johnson & Johnson
|
$634.77B | +25.9% | +6.0% | 30.6 | 1.1% |
|
ABBV
AbbVie Inc.
|
$458.24B | +13.3% | +8.6% | 127.8 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$323.72B | +26.3% | +1.4% | 36.9 | 1.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GILD | -4.0% | +4.6% | -5.7% | +3.6% | +7.2% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -2.3% | +3.9% | -12.1% | +4.7% | -1.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.